Paper Details

  1. Home
  2. Paper Details

Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.

Author: BalaianLarisa, BallEdward D

Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study examined the potential for anti-CD33 monoclonal antibody (mAb) and chemotherapy agents (CA) to cooperate in inhibiting growth of primary AML samples and AML cell lines.
Paper Details　
Original Abstract of the Article :
Chemotherapy agents (CA) such as cytosine arabinoside (ara-C), idarubicin (IDA), and etoposide (VP-16) are widely used in the treatment of acute myeloid leukemia (AML) However, their effects on signaling pathways leading to cytotoxicity have only been described recently. Ligation of the leukemia-ass...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.exphem.2004.11.004

データ提供：米国国立医学図書館（NLM）

Anti-CD33 Monoclonal Antibodies: A New Weapon in the Fight Against Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a devastating disease, often feeling like a vast and unforgiving desert. This study investigates the potential of using anti-CD33 monoclonal antibodies, a type of targeted therapy, to enhance the effectiveness of chemotherapy drugs in treating AML. It's like finding a new weapon in the fight against this deadly disease.

Synergistic Effects of Anti-CD33 Antibodies and Chemotherapy Drugs

The researchers discovered that anti-CD33 monoclonal antibodies can increase the cytotoxic effects of chemotherapy drugs like cytosine arabinoside (ara-C) and idarubicin (IDA) on AML cells. This synergistic effect is like combining two different weapons to create a more powerful force against the cancer cells.

A Promising New Avenue for AML Treatment

This study suggests a promising new avenue for treating AML. By combining anti-CD33 monoclonal antibodies with chemotherapy drugs, we may be able to target AML cells more effectively and achieve better outcomes. It's like finding a new oasis in the desert, offering a more effective and sustainable way to combat this disease.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the desert of AML treatment. The synergistic effects of anti-CD33 monoclonal antibodies and chemotherapy drugs hold great promise for improving outcomes for AML patients. Further research in this area could lead to new and more effective therapies, offering a brighter future for those battling this challenging disease.

Date :
  1. Date Completed 2005-04-11
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

15676214

DOI: Digital Object Identifier

10.1016/j.exphem.2004.11.004

Related Literature

Article Analysis
・Effects of idarubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.